ANTI-RAGE ANTIBODY

Abstract: the invention relates to an antibody, or an antigen binding fragment thereof, that selectively binds receptor for advanced glycation products (rage) and, ideally, provides for cell internalisation whereby said antibody can act as an antibody-drug-conjugate (adc); a polynucleotide and/or vector encoding the said antibody; a cell transformed with said polynucleotide and/or said vector; a pharmaceutical composition comprising said antibody; an adc comprising said antibody; and the use of said antibody, said adc or said pharmaceutical composition in the treatment of or prevention of a disorder characterised by elevated rage expression, such as cancer.

Inventor(s): Robert Conlan, Deyarina Gonzalez

CPC Classification: C07K16/2803 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250163149